Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Short-term stock returns are largely driven by the perception of near-term earnings per share. Read more here.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Morse Asset Management Inc has significantly increased its stake in Regeneron Pharmaceuticals, boosting its share count by a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Regeneron has not disclosed any specific information regarding its anticipated financial performance for the second quarter 2025, which could lead to investor uncertainty and speculation.

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

With the Trump administration poised to hike tariffs on Canadian goods to 35%, the equities market ended on a down note ...

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.